StreetAlpha.app
Home › Stocks › AGIO

Agios Pharmaceuticals, Inc. (AGIO)

Healthcare
$27.60
▼ −4.03%
LAST CLOSE · NOV 20

Agios is a biopharmaceutical company that sells mitapivat and develops other medicines for rare diseases, mainly blood disorders. It last closed at $27.60 on Nov 20, down 4.03% on the day. The next earnings report for AGIO is expected around Thu, Feb 11, 2027. For the quarter ended Sep 2026, AGIO reported EPS of -$1.09 on revenue of $55.4M, with revenue up 330.0% from a year ago. Over its last 8 reports the stock moved an average of 5.0% the session after earnings. Over the last 12 months AGIO insiders bought $0 of stock on the open market and sold $4.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is AGIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AGIO.

Key Stats

Last 12 months
Results
Revenue
$140.8M
+214.4% vs a year ago
Net income
−$372.9M
−264.8% margin
EPS (diluted)
−$6.31
Free cash flow
−$336.0M
−238.5% margin
Valuation
Market cap
$1.7B
59.8M shares
P/E
–
No P/E while losing money
Price to sales
11.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$128.5M
At Sep 30
Shareholder equity
$979.3M
Shares outstanding
59.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $14.2M$14.2MFY2022FY2023: $26.8M$26.8MFY2023FY2024: $36.5M$36.5MFY2024FY2025: $54.0M$54.0MFY2025

From AGIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · Time not announced
Reported EPS
-$1.09
Quarter ended Sep 2026
Year ago EPS
-$1.78
Same quarter last year
Revenue
$55.4M
+330.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.74Dec '24Mar 2025: -$1.55Mar '25Jun 2025: -$1.93Jun '25Sep 2025: -$1.78Sep '25Dec 2025: -$1.85Dec '25Mar 2026: -$1.69Mar '26Jun 2026: -$1.69Jun '26Sep 2026: -$1.09Sep '26Latest -$1.09
Revenue by quarter
Dec 2024: $10.7MDec '24Mar 2025: $8.7MMar '25Jun 2025: $12.5MJun '25Sep 2025: $12.9MSep '25Dec 2025: $20.0MDec '25Mar 2026: $20.7MMar '26Jun 2026: $44.7MJun '26Sep 2026: $55.4MSep '26Latest $55.4M
How AGIO moved after its last 8 reports
Average move the session after a report ±5.0%
Nov 5, 2026Time not announced−9.9%
Jul 30, 2026Time not announced−6.5%
Apr 29, 2026Time not announced+13.1%
Feb 12, 2026Time not announced+1.3%
Oct 30, 2025Time not announced+2.9%
Jul 31, 2025Time not announced−0.8%
May 1, 2025Time not announced+4.2%
Feb 13, 2025Time not announced+1.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AGIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on AGIO: 0 upgrades, 0 downgrades, 0 initiations
JPMorgan Chase & CoTarget cut
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on AGIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AGIO

Technical Analysis

AGIO · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 15% below its 20 day and 18% below its 50 day average. It is 16% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Nov 5) at $27.57, and the nearest resistance the Pivot at $28.06.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.3%/day
Key levels
$44.0952 week high+59.7%
$33.99100 day average+23.2%
$32.6450 day average+18.3%
$31.89200 day average+15.5%
$31.8220 day average+15.3%
$29.39Swing high (Jun 5)+6.5%
$28.68Pivot R1+3.9%
$28.06Pivot+1.7%
$27.60Last close
$27.57Swing low (Nov 5)−0.1%
$26.97Pivot S1−2.3%
$23.0052 week low−16.7%
Indicators
RSI (14)34.88Weak, oversold below 30Neutral
MACD-1.21Below its signal lineBearish
Stochastic20.9Middle of its rangeNeutral
ADX (14)21.8Weak trend
Williams %R-97.0Oversold below −80, overbought above −20Oversold
CCI (20)-109.3Oversold below −100, overbought above 100Oversold
Rate of change−6.2%Change over 10 sessionsBearish
ATR (14)$1.75Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AGIO

What happened before

See how AGIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AGIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AGIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AGIOHow many large options trades hit AGIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AGIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲130 buying vs 95 selling
  • ▲Held by funds +2.3 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding243238+2.1%
In funds' top 1036−50.0%
Held by funds112.8%110.5%+2.3 pts
New / increased34 / 9636 / 96−1.5%
Reduced / sold out66 / 2964 / 33−2.1%
Put/call ratio0.020.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AGIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AGIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.9M24 sales · 7 insiders
97% of the selling was under pre-arranged trading plans.
2025-12 sold $824K2026-01 sold $78K2026-03 sold $1.3M2026-04 sold $1.2M2026-07 sold $151K2026-08 sold $914K2026-10 sold $371KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 26Sarah GheuensChief Medical OfficerSale plan7,866$37.69$296K
Oct 22Sarah GheuensChief Medical OfficerSale plan1,989$37.53$75K
Aug 4Sarah GheuensChief Medical OfficerSale plan30,000$30.48$914K
Jul 1Sarah GheuensChief Medical OfficerSale plan4,007$37.56$151K
Apr 2Brian GoffCEOSale plan19,068$34.71$662K
Apr 2Krishnan ViswanadhanChief Corp Dev & StrategySale plan2,959$34.71$103K
Every insider buy and sale for AGIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AGIO insider trades →

From SEC Form 4 filings by AGIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGIO is in one of them and how their past AGIO trades turned out.

AGIO in the AI portfolios
Loading…

AGIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AGIO in an article yet. Here's the latest on the wider market.

AGIO in the news

AGIO Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Sep 10
Who traded AGIO · since 2015
Latest 5 filings of 8
$1K – $15KTraded Aug 20, 2026Filed Sep 10, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
$1K – $15KTraded Apr 17, 2025Filed May 6, 2025
$1K – $15KTraded Jan 29, 2025Filed Feb 11, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KAug 20, 2026Sep 10, 202621 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KDec 11, 2025Jan 12, 202632 d
Gilbert CisnerosD · CABuy$1K – $15KApr 17, 2025May 6, 202519 d
Gilbert CisnerosD · CABuy$1K – $15KJan 29, 2025Feb 11, 202513 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Agios Pharmaceuticals

Agios is a biopharmaceutical company that focuses on rare diseases, with a foundation in hematology, the study of blood disorders. Its lead medicine, mitapivat, is sold under the brand names AQVESME and PYRUKYND and is approved to treat anemia in adults with certain rare blood disorders. The company is also developing additional medicines for rare blood and metabolic conditions. Agios is based in Cambridge, Massachusetts, and serves patients and the clinicians who treat them.

Headquarters
Cambridge, MA
Founded
2008